In fact, the latest analysis of the SURPASS-CVOT trial in early 2026 showed that patients on Tirzepatide had a lower incidence of kidney-related problems compared to those on other therapies
Eric Topol, in a July 2025 review of the evidence on peptide therapies, grouped ipamorelin with CJC-1295 and tesamorelin as growth-hormone-related peptides that "carry the potential risk of cancer" on mechanistic grounds, because sustained IGF-1 elevation promotes cell proliferation broadly [4]
It should include the clinical reason for prescribing the compounded version, such as a drug shortage
Ipamorelin is more restricted, with stronger selectivity data but weaker body-composition evidence
Beyond the immediate benefits, significant health improvements such as better blood pressure control, cholesterol management, and balanced blood sugar levels are common, reflecting Semaglutide's holistic approach to health improvement